A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-09-05
Target enrollment:
Participant gender:
Summary
Despite the success of anti-angiogenic therapy in multiple treatment settings, a fraction of
patients are refractory to vascular endothelial growth factor (VEGF) inhibitor treatment,
while the majority of patients will eventually develop evasive resistance. It is proposed
that mesenchymal-epithelial transition factor (c-MET) and its ligand hepatocyte growth factor
(HGF or scatter factor) contribute to VEGF inhibitor resistance, such that combining a c-MET
inhibitor with a VEGF inhibitor will provide additional clinical activity compared to VEGF
inhibitor alone. This hypothesis will be tested using the cMET/ALK inhibitor, crizotinib, in
combination with the VEGF inhibitor, axitinib.Since this will be the first study of axitinib
given in combination with crizotinib, the study will primarily assess the safety and
tolerability of the combination regimen.